Efficacy and Safety of Sacral Neuromodulation With InterStim II in Neurogenic Bladder and/or Bowel Patients

Status: Unknown
Location: See location...
Intervention Type: Device
Study Type: Observational
SUMMARY

The goal of this observational study is to evaluate efficacy and safety of sacral neuromodulation in neurogenic patients compared to non-neurogenic (idiopathic) patients. \[. The main question\[s\] it aims to answer are: * determine efficacy and safety of the therapy in neurogenic patients. * compare outcomes of the therapy to idiopathic patients. If there is a comparison group: Researchers will compare the outcomes of the therapy between the neurogenic and non-neurogenic subset of patients.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients who underwent InterStim II advanced evaluation for approved indication

Locations
Other Locations
Israel
Meir Medical Center
Kfar Saba
Time Frame
Start Date: 2021-12-19
Completion Date: 2024-12-31
Participants
Target number of participants: 100
Treatments
Neurogenic Patients
Patients with underlined relevant neurologic condition, with either neurogenic bladder or bowel, after advanced evaluation of InterStim II
Idiopathic
Patients without underlined relevant neurologic condition, after advanced evaluation of InterStim II
Sponsors
Leads: Omri Schwarztuch Gildor

This content was sourced from clinicaltrials.gov